ClinicalTrials.gg
RecruitingNCT06057597YOMEGA-2Updated Feb 27, 2026

Omega Gastric Bypass (150cm) Compared to the Roux-en-Y Gastric Bypass (YOMEGA-2 Multicentric Trial)

An interventional study of Laparoscopic OAGB and Laparoscopic RYGB in Obesity and Morbid, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
368
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 58 studies in Obesity by Assistance Publique - Hôpitaux de Paris — 16 open to participants now, 16 under way, 1 of them phase 3. Obesity · Assistance Publique - Hôpitaux de Paris.

Planned enrollment
7th of 38
368 · median 110
Started
2023
with 2 others
No phase
30 of 58
9 open now
Primary completion
2028-10
later than 12 of 15 live
Registered
48th of 58
by date

Among the 58 studies in Obesity by Assistance Publique - Hôpitaux de Paris, this one is the 7th largest by planned enrollment of the 38 interventional ones that give a count, is one of 3 that started in 2023, is one of 30 with no phase, reaches primary completion later than 12 of the 15 other live ones, and was the 48th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

16 of the 58 studies in Obesity by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

Where they have run

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Obesity by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

Obesity with its consequences such as type 2 diabetes, high blood pressure, dyslipidemia, fatty liver disease, sleep apnea and cancers, remains a major healthcare problem worldwide. Bariatric surgery, combined with nutritional education and close monitoring, has been shown to be the most effective treatment for patients with morbid obesity resulting in significant and lasting weight loss and improvements in co-morbidities . With nearly 50000 procedures per year France ranks third in the world in terms of care for patients suffering from morbid (BMI ≥ 40 kg/m²) and severe (BMI 35-40 kg/m²) obesity.

In parallel with the significant increase in the number of patients operated on for obesity in the world, over the past two decades, significant development has been observed in the field of bariatric surgery with a decrease or even disappearance of some procedures and the appearance of others.

Performed for more than 40 years, the Roux-en-Y Gastric Bypass (RYGB) is a restrictive and malabsorptive procedure and currently is considered as gold standard procedure for the treatment of morbid obesity and its comorbidities. However, despite the good effectiveness (with an average Excess Weight Loss % (EWL%) of approximatively 70% at 2 years), RYGB is technically demanding procedure with learning curve requiring more than 100 cases and an overall complication rate ranging from 10% to 20% Introduced in 2001, one anastomosis gastric bypass (OAGB) is a modified gastric bypass that consists of a single gastrojejunal anastomosis between a long gastric pouch and a jejunal (biliopancreatic) omega loop. In Sept. 2019, taking into account the results from YOMEGA trial, the French High Authority for Health (Haute Autorité de Santé (HAS)) recommended to ban OAGB with 200 cm or longer BPL and urged to assess the efficacy and safety of OAGB with 150 cm BPL in a randomized controlled trial. Indeed, YOMEGA-2 trial is logical continuity of the YOMEGA trial.

The aim of this study is to assess weight loss efficiency and the nutritional safety of the OAGB-150 in comparison to a standard (RYGB).

The hypothesis of this study is that the OAGB with a 150 cm BPL could have the same efficacy on weight loss and nutritional complication rate in comparison to the RYGB at 2 years.

03

Conditions studied

  • Obesity
  • Morbid

Browse trials for

Keywords

  • Bariatric surgery
  • RYGB
  • MGB/OAGB
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient aged from 18 to 65 years old
  • Type III obesity ( ≥ 40 kg/m²), or Type II obesity BMI 35-40 kg/m2 associated with at least one co-morbidity which will be improved by surgery (high blood pressure, type 2 diabetes mellitus, obstructive sleep apnea, dyslipidemia, arthrosis)
  • Patient who had benefited from an Upper GI Endoscopy with to look for Helicobacter pylori within 12 months before surgery
  • Patient who has benefited from a multidisciplinary evaluation at least 6 months, with a favorable opinion for a gastric bypass
  • Patient who understood and accepted the need for a long-term follow-up
  • Patient who agreed to be included in the study and who signed the form
  • Patient affiliated to a social security scheme
  • For child-bearing aged women, efficient

Exclusion criteria

Exclusion Criteria:

  • History of previous bariatric surgery
  • History of chronic inflammatory bowel disease
  • Presence of chronic diarrhea
  • Presence of a severe and evolutive life threatening pathology
  • Presence of dysplastic modifications of the gastric mucosa, chronic atrophic gastritis or history of gastric cancer
  • Presence of an unhealed gastro-duodenal ulcer
  • Presence of Helicobacter pylori resistant to medical treatment
  • Presence of esophagitis
  • Pregnancy or desire to be pregnant during the study
  • Mentally unbalanced patients, under supervision or guardianship
  • Patients who don't understand French and not able to give consent
  • Patient included and followed in another interventional trial
  • Unable to consent, under tutelage or curatorship, or judiciary safeguard
  • Presence of type 1 diabetes
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
368 participants (estimated)

Study arms

  • Experimental
    Experimental group

    This corresponds to patients with type 2 obesity (BMI 35-40) with comorbidities (high blood pressure, type 2 diabetes mellitus, obstructive sleep apnea, dyslipidemia, arthrosis) and type 3 obesity (BMI ≥ 40 kg/m²) and candidates for bariatric surgery. Laparoscopic OAGB will be performed with long and narrow gastric pouch (30cc) and 150 cm biliopancreatic limb

    Procedure: Laparoscopic OAGB

  • Active comparator
    Control Groupe

    This corresponds to patients with type 2 obesity (BMI 35-40) with comorbidities (high blood pressure, type 2 diabetes mellitus, obstructive sleep apnea, dyslipidemia, arthrosis) and type 3 obesity (BMI ≥ 40 kg/m²) and candidates for bariatric surgery. Standard laparoscopic RYGB will be performed with a gastric pouch (30cc) and 150 cm antecolic Roux limb and a 50 cm biliopancreatic limb.

    Procedure: Laparoscopic RYGB

Interventions

  • ProcedureLaparoscopic OAGB

    It is a gastric bypass surgery with a unique gastro-jejunal anastomosis, a long (11-14cm) and narrow (3-4cm) gastric pouch will be created by applying one horizontal 45-mm stapler at the angle of lesser curvature, just above the left branch of the crow's foot, and then four to five vertical 60-mm staple cartridges will be placed upwards to the angle of His, and calibrated along a 32-Fr bougie. Sectioning of the greater omentum into a bivalve will be performed. The jejunum will be measured using pre-measured strip and amounted antecolically at 150 cm from the ligament of Treitz. An end-to-side anastomosis will be performed with the gastric pouch, using a 45-mm linear stapler and an anterior running suture to close gastro-enterotomy.

    Also known as: One Anastomosis Gastric Bypass / Mini Gastric Bypass

  • ProcedureLaparoscopic RYGB

    A small gastric pouch (30cc) will be created using a linear stapler. The alimentary limb will be moved up into an antecolic position after an epiploic transection so as to perform the gastro-jujunal anastomosis. The gastro-jejunostomy will be performed manually or using a linear or circular stapler. An alimentary limb of 150 cm and a biliary limb of 50cm will be measured (using premeasured strip) in order to perform the latero-lateral jejuno-jejunal anastomosis using a linear stapler. All mesenteric defects (Petersen's space and mesenteric defect) will be closed with a non-absorbable running suture

    Also known as: Roux-en-Y Gastric Bypass

06

What researchers measure

Primary outcomes

  1. To demonstrate that OAGB with 150 cm biliopancreatic limb is not inferior to RYGB on weight loss (efficacy).

    For each patient co-primary endpoints will be assessed at 2 years after surgery composed by: Efficacy: Weight loss according to Excess Weight Loss % (EWL%) calculated using the following formula: ((weight 2 years after surgery - initial weight) / (initial weight - ideal weight)) x 100. Ideal weight defined as the weight corresponding to a BMI = 25 kg/m². The assessment of the primary co-endpoint will be standardized between the sites.

    Time frame: 2 years after the surgery

  2. To demonstrate that OAGB with 150 cm biliopancreatic limb is not inferior to RYGB on nutritional complication rate (safety)

    For each patient co-primary endpoints will be assessed at 2 years after surgery composed by: Safety: Nutritional complications defined by at least one vitamin deficiency (vit. B1 \< 66nmol/l or B12 \< 145pmol/l), malnutrition (albumin \< 30g/l), anemia (hemoglobin \< 10g/dl) or a combination of these. The assessment of the primary co-endpoint will be standardized between the sites.

    Time frame: 2 years after the surgery

Secondary outcomes

  1. Measurement of albumin

    Measurement of albumin will explore the nutritional status of patients. Results will be expressed in g/l

    Time frame: Before and 1, 3, 6, 12, 18 and 24 months after surgery

  2. Measurement of pre-albumin

    Measurement of pre-albumin will explore the nutritional status of patients. Results will be expressed in g/l

    Time frame: Before and 1, 3, 6, 12, 18 and 24 months after surgery

  3. Measurement of hemoglobin

    Measurement of hemoglobin will explore the nutritional status of patients. Results will be expressed in g/l

    Time frame: Before and 1, 3, 6, 12, 18 and 24 months after surgery

  4. Measurement of calcium

    Measurement of calcium will explore the nutritional status of patients. Results will be expressed in mmol/l

    Time frame: Before and 1, 3, 6, 12, 18 and 24 months after surgery

  5. Measurement of ferritin

    Measurement of ferritin will explore the nutritional status of patients. Results will be expressed in μg/l

    Time frame: Before and 1, 3, 6, 12, 18 and 24 months after surgery

  6. Measurement of iron

    Measurement of iron will explore the nutritional status of patients. Results will be expressed in mmol/l

    Time frame: Before surgery and 1, 3, 6, 12, 18 and 24 months after surgery

  7. Measurement of % of transferrin saturation

    Measurement of % of transferrin saturation will explore the nutritional status of patients. Results will be expressed in %

    Time frame: Before surgery and 1, 3, 6, 12, 18 and 24 months after surgery

  8. Measurement of zinc

    Measurement of zinc will explore the nutritional status of patients. Results will be expressed in mmol/L

    Time frame: Before surgery and 6, 12 months and 24 months after surgery

  9. Measurement of vitamin A

    Measurement of vitamin A will explore the nutritional status of patients. Results will be expressed in mmol/l

    Time frame: Before surgery and 6, 12 and 24 months after surgery

  10. Measurement of vitamin B1

    Measurement of vitamin B1 will explore the nutritional status of patients. Results will be expressed in nmol/l

    Time frame: Before surgery and 6, 12 and 24 months after surgery

  11. Measurement of vitamin B9

    Measurement of vitamin B9 will explore the nutritional status of patients. Results will be expressed in nmol/l

    Time frame: Before surgery and 6, 12 and 24 months after surgery

  12. Measurement of vitamin B12

    Measurement of vitamin B12 will explore the nutritional status of patients. Results will be expressed in pmol/l

    Time frame: Before surgery and 6, 12 and 24 months after surgery

  13. Measurement of vitamin E

    Measurement of vitamin E will explore the nutritional status of patients. Results will be expressed in mmol/l

    Time frame: Before surgery and 6, 12 and 24 months after surgery

  14. Measurement of vitamin D

    Measurement of vitamin D will explore the nutritional status of patients. Results will be expressed in nmol/l

    Time frame: Before surgery and 6, 12 and 24 months after surgery

  15. Measurement of prothrombin rate

    Measurement of prothrombin rate will explore the nutritional status of patients. Results will be expressed in %

    Time frame: Before surgery and 6, 12 and 24 months after surgery

  16. Measurement of the 24-hour steatorrhea rate

    Measurement of the average number of stool will explore the nutritional status of patients. Results will be expressed in number of stool/day

    Time frame: 6 month after surgery

  17. Measurement of HbA1c

    Measurement of HbA1c will explore the Metabolic efficiency of surgery. Results will be expressed in %

    Time frame: Before surgery and 1, 3, 6, 12, 18 and 24 months after surgery

  18. Measurement of fasting glycemia

    Measurement of fasting glycemia will explore the Metabolic efficiency of surgery. Results will be expressed in mmol/l

    Time frame: Before surgery and 1, 3, 6, 12, 18 and 24 months after surgery

  19. Measurement of HDL

    Measurement of HDL will explore the Metabolic efficiency of surgery. Results will be expressed in mmol/l

    Time frame: Before surgery and 1, 3, 6, 12, 18 and 24 months after surgery

  20. Measurement of LDL

    Measurement of LDL will explore the Metabolic efficiency of surgery. Results will be expressed in mmol/l

    Time frame: Before surgery and 1, 3, 6, 12, 18 and 24 months after surgery

  21. Measurement of cholesterol

    Measurement of cholesterol will explore the Metabolic efficiency of surgery. Results will be expressed in mmol/l

    Time frame: Before surgery and 1, 3, 6, 12, 18 and 24 months after surgery

  22. Measurement of triglycerides

    Measurement of triglycerides will explore the Metabolic of surgery. Results will be expressed in mmol/l

    Time frame: Before surgery and 1, 3, 6, 12, 18 and 24 months after surgery

  23. Evaluation of antidiabetic drugs

    Assessment of number of antidiabetic medications will explore the Metabolic efficiency of surgery. This outcome will be expressed in terms of increase, decrease, discontinuation or restart of treatment.

    Time frame: Before surgery and 6, 12 and 24 months after surgery

  24. Evaluation of antilipidemic drugs

    Assessment of the number of antilipidemic medications will explore the Metabolic efficiency of surgery. This outcome will be expressed in terms of increase, decrease, discontinuation or restart of treatment

    Time frame: Before surgery and 6, 12 and 24 months after surgery

  25. Evaluation of antihypertensive drugs

    Assessment of the number of antihypertensive medications will explore the Metabolic efficiency of surgery. This outcome will be expressed in terms of increase, decrease, discontinuation or restart of treatment.

    Time frame: Before surgery and 6, 12 and 24 months after surgery

  26. Evaluation of the use of Continuous Positive Airway Pressure for Obstructive Sleep Apnea

    Evolution of the use of Continuous Positive Airway Pressure for Obstructive Sleep Apnea will explore the Metabolic efficiency of surgery. This outcome will be expressed in terms of the use or discontinuation of the use of Continuous Positive Airway Pressure machine

    Time frame: Before surgery and 6, 12 and 24 months after surgery

  27. Hospitalization length

    The Length of stay (in days) is based on the number of days of hospitalization from surgery (day of surgery = D0) until the end of hospitalization.

    Time frame: The last day of hospitalization

  28. Number of patients readmitted

    Number of patients readmitted within 30 days after surgery.

    Time frame: 30 days after surgery

  29. Occurrence of kidney stone

    For each visit after the surgery, the presence or not of kidney stones will be documented and if applicable the treatment will be noted

    Time frame: Within 2 years after surgery

  30. Overall complications rate

    Rate of medical and surgical (\> or = grade III) complications within 24 months after surgery using the Dindo-Clavien classification, described as : Grade I = Any deviation from the normal postoperative course. Grade II = Requiring pharmacological treatment with drugs other than such allowed for grade I complications. Grade III = Requiring surgical, endoscopic or radiological intervention, not under (Grade IIIa) or under general anesthesia (Grade IIIb) Grade IV = Life-threatening complication with single organ (Grade IVa) or Multiorgan dysfunction (Grade IVb) Grade V = Death of a patient.

    Time frame: Within 24 months after surgery

  31. Type of early complications

    Type (medical or surgical) of early complications (within 30 days) for each procedure.

    Time frame: Within 30 days after surgery

  32. Severity of early complications

    Severity of early complications (within 30 days) for each procedure according to the Dindo-Clavien classification

    Time frame: Within 30 days after surgery

  33. Type of late complications

    Type (medical or surgical) of late complications (after 30 days) for each procedure.

    Time frame: Within 2 years after surgery

  34. Severity of late complications

    Severity of late complications (after 30 days) for each procedure according to the Dindo-Clavien classification

    Time frame: Within 2 years after surgery

  35. Gastroesophageal reflux assessment

    Evolution of gastroesophageal reflux will be assessed at each study visit, before and after surgery. This outcome will be expressed in terms of improvement, aggravation or onset.

    Time frame: Before surgery and 1, 3, 6, 12, 18 and 24 months after surgery

  36. Absolute weight loss assessment

    Weight loss at 1, 3, 6, 12, 18 and 24 months after surgery, according to absolute weight loss (aWL) in kg.

    Time frame: 1, 3, 6, 12, 18 and 24 months after surgery

  37. Excess Weight Loss percentage assessment

    Weight loss at 1, 3, 6, 12, 18 and 24 months after surgery, according to Excess Weight Loss percentage (EWL%), calculated using the following formula: ((weight at visit X - initial weight) / (initial weight - ideal weight)) X 100

    Time frame: 1, 3, 6, 12, 18 and 24 months after surgery

  38. Excess BMI Loss percentage assessment

    Weight loss at 1, 3, 6, 12, 18 and 24 months after surgery, according Excess BMI Loss percentage (EBL%), according to the formula : ((BMI at visit X - initial BMI) / (initial BMI - ideal BMI)) X 100 with Ideal BMI = 25 kg/m²

    Time frame: 1, 3, 6, 12, 18 and 24 months after surgery

  39. Quality of life assessed with GIQLI questionnaire

    This questionnaire consists of 36 items exploring 5 dimensions or subscales: symptoms, physical condition, emotions, social integration and the effect of any medical treatment. For each item, 5 responses will be proposed to the patients and for each answer, a score ranging from 0 to 4 (highest score = 144) will be assigned. A high score defines a more favorable health state

    Time frame: Before surgery and at 6, 12 and 24 months after surgery

  40. Quality of life assessed with SF36 questionnaire

    This questionnaire taps eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/tiredness, and general health perceptions. It also includes a single item that provides an indication of a perceived change in health

    Time frame: Before surgery and at 6, 12 and 24 months after surgery

  41. Quality of life assessed with Sigstad questionnaire

    The Sigstad questionnaire allows the identification and diagnosis of postoperative dumping syndrome and early hypoglycaemia: a score \>7 suggests a dumping syndrome

    Time frame: Before surgery and at 1, 3, 6, 12, 18 and 24 months after surgery

  42. Body composition

    Body composition level on a subsample of the total population: By impedancemetry : * Muscle mass index in kg/m2 * Non-fat mass index in kg/m2 * Fat mass index in kg/m2

    Time frame: Before and 24 months after surgery.

  43. Sarcopenia level

    Sarcopenia level on a subsample of the total population will be assessed by Handgrip Strength

    Time frame: Before and 24 months after surgery.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Oct 2028, 58 months after the start.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 58 months is above that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2023
First posted
Sep 28, 2023
StartActual
Nov 13, 2023
Primary completionEst.
Oct 1, 2028
CompletionEst.
Dec 1, 2028
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06057597
Responsible party
Sponsor
First posted
Sep 28, 2023
Start date
Nov 13, 2023
Primary completion
Oct 1, 2028 (estimated)
Completion
Dec 1, 2028 (estimated)
Last update
Feb 27, 2026

Study contacts

Tigran POGHOSYAN, MD-PhD
Contact
tigran.poghosyan@aphp.fr
33 1 40 25 82 39
Tigran POGHOSYAN, MD-PhD
principal investigator · Bichat (APHP)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion